Last reviewed · How we verify
Etoposide, carboplatin, melphalan, cisplatin, thiotepa
Etoposide, carboplatin, melphalan, cisplatin, thiotepa is a alkylating agents Small molecule drug developed by Gustave Roussy, Cancer Campus, Grand Paris. It is currently in Phase 2 development for Small cell lung cancer, Non-small cell lung cancer, Ovarian cancer.
Etoposide, carboplatin, melphalan, cisplatin, and thiotepa are chemotherapeutic agents that work by interfering with DNA replication and cell division, ultimately leading to cell death.
Etoposide, carboplatin, melphalan, cisplatin, and thiotepa are chemotherapeutic agents that work by interfering with DNA replication and cell division, ultimately leading to cell death. Used for Small cell lung cancer, Non-small cell lung cancer, Ovarian cancer.
At a glance
| Generic name | Etoposide, carboplatin, melphalan, cisplatin, thiotepa |
|---|---|
| Sponsor | Gustave Roussy, Cancer Campus, Grand Paris |
| Drug class | alkylating agents |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
These drugs are classified as alkylating agents, which form covalent bonds with DNA, causing cross-linking and DNA damage. This damage triggers cell death, particularly in rapidly dividing cancer cells. The specific mechanism of action varies slightly between each drug, but they all ultimately disrupt DNA replication and cell division.
Approved indications
- Small cell lung cancer
- Non-small cell lung cancer
- Ovarian cancer
- Testicular cancer
- Breast cancer
Common side effects
- Myelosuppression
- Nausea and vomiting
- Neutropenia
- Anemia
- Thrombocytopenia
Key clinical trials
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
- Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) (PHASE3)
- Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma (PHASE2)
- High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) (PHASE3)
- Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma (PHASE3)
- Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma (PHASE2)
- Response Based Treatment for Children With Unresectable Localized Soft Tissue Sarcoma (PHASE2)
- Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Neuroblastoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Etoposide, carboplatin, melphalan, cisplatin, thiotepa CI brief — competitive landscape report
- Etoposide, carboplatin, melphalan, cisplatin, thiotepa updates RSS · CI watch RSS
- Gustave Roussy, Cancer Campus, Grand Paris portfolio CI
Frequently asked questions about Etoposide, carboplatin, melphalan, cisplatin, thiotepa
What is Etoposide, carboplatin, melphalan, cisplatin, thiotepa?
How does Etoposide, carboplatin, melphalan, cisplatin, thiotepa work?
What is Etoposide, carboplatin, melphalan, cisplatin, thiotepa used for?
Who makes Etoposide, carboplatin, melphalan, cisplatin, thiotepa?
What drug class is Etoposide, carboplatin, melphalan, cisplatin, thiotepa in?
What development phase is Etoposide, carboplatin, melphalan, cisplatin, thiotepa in?
What are the side effects of Etoposide, carboplatin, melphalan, cisplatin, thiotepa?
Related
- Drug class: All alkylating agents drugs
- Manufacturer: Gustave Roussy, Cancer Campus, Grand Paris — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Small cell lung cancer
- Indication: Drugs for Non-small cell lung cancer
- Indication: Drugs for Ovarian cancer